ConductScience.org, home

Paper24893003

Phage neutralization by sera of patients receiving phage therapy.

Łusiak-Szelachowska M and 11 others. Viral Immunol, 2014. Cited by 173 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Phage neutralization by sera of patients receiving phage therapy. Papers, record 24893003. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24893003

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phage neutralization by sera of patients receiving phage therapy.
PubMed
Journal
Viral Immunol
PubMed
Year
2014
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
173
iCite
Relative citation ratio, by iCite
6.31
iCite
Revised in PubMed
2024-03-21
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Łusiak-Szelachowska MMarzanna
2Zaczek MMaciej
3Weber-Dąbrowska BBeata
4Międzybrodzki RRyszard
5Kłak MMarlena
6Fortuna WWojciech
7Letkiewicz SSławomir
8Rogóż PPaweł
9Szufnarowski KKrzysztof
10Jończyk-Matysiak EEwa
11Owczarek BBarbara
12Górski AAndrzej

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, ViralMajor topic
Bacterial InfectionsMajor topic
BacteriophagesMajor topic
Case-Control Studies
Enzyme-Linked Immunosorbent Assay
Humans
Neutralization Tests
Virus Inactivation

Source PubMed

References9

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119,066,828Preparation and characterization of anti-phage serum.Methods Mol Biol2009https://conductscience.org/library/papers/19066828PubMed
24,273,800Antibodies against staphylococcal bacteriophages in human sera. I. Assay of antibodies in healthy individuals and in patients with staphylococcal infections.Acta Pathol Microbiol Scand B Microbiol Immunol1973https://conductscience.org/library/papers/4273800PubMed
33,455,646Immunogenic effect of bacteriophage in patients subjected to phage therapy.Arch Immunol Ther Exp (Warsz)1987https://conductscience.org/library/papers/3455646PubMed
415,980,363Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy.Antimicrob Agents Chemother2005https://conductscience.org/library/papers/15980363PubMed
522,748,808Phage as a modulator of immune responses: practical implications for phage therapy.Adv Virus Res2012https://conductscience.org/library/papers/22748808PubMed
64,273,801Antibodies against staphylococcal bacteriophages in human sera. II. Assay of antibodies in exacerbation and regression of chronic staphylococcal osteomyelitis.Acta Pathol Microbiol Scand B Microbiol Immunol1973https://conductscience.org/library/papers/4273801PubMed
75,416,642The serum antibody response to bacteriophage phi chi 174 in germ-free and conventionally reared mice. II. Kinetics of the serum antibody response following primary immunization.Immunology1970https://conductscience.org/library/papers/5416642PubMed
821,908,031Effect of rituximab on human in vivo antibody immune responses.J Allergy Clin Immunol2011https://conductscience.org/library/papers/21908031PubMed
922,748,809Clinical aspects of phage therapy.Adv Virus Res2012https://conductscience.org/library/papers/22748809PubMed

Cited by129

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 173 citations.

PMIDTitleJournalYearIn PapersSource
42,979,208Phage therapy against Pseudomonas aeruginosa biofilm infections: challenges and advanced strategies.Front Microbiol2026https://conductscience.org/library/papers/42979208PubMed
42,938,771Novel Therapeutic Strategies for Preventing Recurrent Urinary Tract Infections in Women: A Narrative Review.Antibiotics (Basel)2026https://conductscience.org/library/papers/42938771PubMed
42,614,511Assessment of water prophylaxis and biosafety in finfish aquaculture - current and emerging technologies.Front Microbiol2026https://conductscience.org/library/papers/42614511PubMed
42,597,638Harnessing phages in the age of antibiotic resistance: immunological perspectives.Front Immunol2026https://conductscience.org/library/papers/42597638PubMed
42,491,532Bacteriophage therapy for controlling poultry production problems.Iran J Vet Res2025https://conductscience.org/library/papers/42491532PubMed
42,436,825Mechanisms of Resistance, Insights From Case Reports, and Future Prospects in Mycobacteriophage Therapy.J R Soc N Z2026https://conductscience.org/library/papers/42436825PubMed
42,367,797Innate immune recognition and immunomodulatory effects of bacteriophages: implications for phage therapy.Front Immunol2026https://conductscience.org/library/papers/42367797PubMed
42,263,718Calciphylaxis complicated by NDM-1-producing Pseudomonas aeruginosa: first experience with cefepime-zidebactam alongside phage therapy in the USA.Lancet Infect Dis2026https://conductscience.org/library/papers/42263718PubMed
42,231,337Antibacterial potential of five phages in controlling Enterococcus faecalis and Enterococcus faecium.Virol J2026https://conductscience.org/library/papers/42231337PubMed
42,146,041A review on phytochemical and bacteriophage based therapeutic strategies for the management of Brucellosis.Front Vet Sci2026https://conductscience.org/library/papers/42146041PubMed
42,032,071Cross-reactive anti-prophage antibodies and bacterial heteroresistance implicated in phage therapeutic failure.Nat Med2026https://conductscience.org/library/papers/42032071PubMed
41,946,778Assessing the impact of phage therapy on growth performance, microbiome and phage specific immune response in chickens.Sci Rep2026https://conductscience.org/library/papers/41946778PubMed
41,892,478Bacteriophage Therapy Against Shigella spp.: A Precision Antimicrobial Strategy.Antibiotics (Basel)2026https://conductscience.org/library/papers/41892478PubMed
41,853,532Bacteriophages: a double-edged sword in the gastrointestinal tract.Front Microbiomes2024https://conductscience.org/library/papers/41853532PubMed
41,750,453Bacteriophage-Based Control of Methicillin-Resistant Staphylococcus aureus: Anti-Biofilm Activity, Surface-Active Formulation Compatibility, and Genomic Context.Antibiotics (Basel)2026https://conductscience.org/library/papers/41750453PubMed
41,516,055Analysis of Pro- and Anti-Inflammatory Gene Response Patterns in Patients Receiving Phage Therapy.Int J Mol Sci2025https://conductscience.org/library/papers/41516055PubMed
41,065,359In vitro activity of antibiotic monotherapy and combination therapy with bacteriophages against Staphylococcus aureus LVAD-driveline infections.J Clin Microbiol2025https://conductscience.org/library/papers/41065359PubMed
40,358,692Phage Therapy for Urinary Tract Infections: Progress and Challenges Ahead.Int Urogynecol J2025https://conductscience.org/library/papers/40358692PubMed
39,866,829Phage therapy in the management of respiratory and pulmonary infections: a systematic review.Ther Adv Infect Dis2025https://conductscience.org/library/papers/39866829PubMed
39,861,891Selected Mechanisms of Action of Bacteriophages in Bacterial Infections in Animals.Viruses2025https://conductscience.org/library/papers/39861891PubMed

See all 129 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24893003

GET https://conductscience.org/api/papers/v1/24893003/cited_by?page=2